Compare Genuine Parts Company (GPC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Twist Bioscience Corp — how do they compare? Genuine Parts Company trades at $126.99 (market cap $17.67B), while Twist Bioscience Corp trades at $160.14 (market cap $10.08B). The key difference: Genuine Parts Company is the larger of the two by market cap, and Genuine Parts Company pays a 3.32% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Twist Bioscience Corp for 27 Days on average.
| GPC | TWST | |
|---|---|---|
Market Cap | $17.67B | $10.08B |
Volume | 1,079,458 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $205.00 |
52-Week Low | $92.47 | $25.45 |
Typical Hold Time | 75 Days | 27 Days |
Enterprise Value | $23.76B | $10.01B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $127.16, up 1.4% today, near its pivot point of $127 with technical indicators showing a bullish trend. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, with Q3 2026 results due October 20. Revenue growth is steady, but net income margins have compressed significantly to 0.13% in 2025. Analysts maintain a consensus price target of $145.75, with 43% recommending Buy. Key developments include the planned spinoff of its industrial unit, Motion, scheduled for Q1 2027.
The outlook for GPC is cautiously optimistic, driven by the potential value unlock from the corporate split and its position in the resilient automotive aftermarket. However, thin profit margins and rising debt levels pose risks. The stock offers a dividend yield supported by its Dividend King status, but investors should weigh execution risks around the separation against the prospect of segment-specific reratings.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
